Přejít k obsahu
Merck
Všechny fotografie(1)

Key Documents

View All Documentation

H-001

Supelco

Hydrochlorothiazide solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Přihlásitk zobrazení cen stanovených pro organizaci a smluvních cen
Všechny fotografie(1)

About This Item

Empirický vzorec (Hillův zápis):
C7H8ClN3O4S2
Číslo CAS:
58-93-5
Molekulová hmotnost:
297.74
EC Number:
200-659-6
UNSPSC Code:
41116107
NACRES:
NA.24

grade

certified reference material

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in methanol

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

clinical testing

format

single component solution

storage temp.

−20°C

SMILES string

NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1Cl

InChI

1S/C7H8ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-2,10-11H,3H2,(H2,9,12,13)

InChI key

JZUFKLXOESDKRF-UHFFFAOYSA-N

Gene Information

human ... SLC12A3(6559)

Související kategorie

General description

Hydrochlorothiazide is a calcium-sparing diuretic used for treatment of edema and hypertension. A thiazide derivative, hydrochlorothiazide is sold under the trade names Microzide® and Aquazide H. This Certified Spiking Solution® is suitable for use in LC/MS or GC/MS applications such as clinical toxicology and forensic analysis.

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Microzide is a registered trademark of Watson Laboratories, Inc.
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

target_organs

Eyes,Central nervous system

Storage Class

3 - Flammable liquids

wgk_germany

WGK 2

flash_point_f

49.5 °F - closed cup

flash_point_c

9.7 °C - closed cup

Osvědčení o analýze (COA)

Vyhledejte osvědčení Osvědčení o analýze (COA) zadáním čísla šarže/dávky těchto produktů. Čísla šarže a dávky lze nalézt na štítku produktu za slovy „Lot“ nebo „Batch“.

Již tento produkt vlastníte?

Dokumenty související s produkty, které jste v minulosti zakoupili, byly za účelem usnadnění shromážděny ve vaší Knihovně dokumentů.

Navštívit knihovnu dokumentů

Zákazníci si také prohlíželi

Slide 1 of 3

1 of 3

Dexamethasone solution 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

D-085

Dexamethasone solution

Salbutamol

Sigma-Aldrich

S8260

Salbutamol

Phenacetin melting point standard Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1094

Phenacetin melting point standard

Yoshihisa Hanayama et al.
Acta medica Okayama, 66(6), 449-459 (2012-12-21)
Angiotensin receptor blockers (ARBs) are the first-line antihypertensive agents. In clinical practice, it is often difficult to achieve the recommended blood pressure level by ARBs in their ordinal dosages alone. This study examined the practical efficacy of a combination therapy
Miguel Angel Arrabal-Polo et al.
Urology, 81(4), 731-737 (2013-02-05)
To analyze the effects of aminobisphosphonates and thiazides on renal lithogenic activity and bone mineral density in patients with recurring renal calcium lithiasis. A prospective cohort study with 3 years of clinical follow-up data was performed. The study included 2
Successful rapid desensitization to hydrochlorothiazide.
Jamma Li et al.
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 110(4), 307-308 (2013-03-29)
Sympathetic activation and endothelial dysfunction as therapeutic targets in obesity-related hypertension.
Brent Egan et al.
Journal of hypertension, 31(2), 259-260 (2013-01-11)
R R Tjandrawinata et al.
Drug research, 63(5), 243-249 (2013-03-30)
The present study was conducted to compare the bioavailability of 2 formulations of fixed-dose combination of bisoprolol fumarate 5 mg and hydrochlorotiazide (HCT) 6.25 mg film-coated tablet (test and reference formulations). This study was a randomized, single-blind, 2-period, 2-sequence cross-over
Zobrazit všechny související dokumenty

Náš tým vědeckých pracovníků má zkušenosti ve všech oblastech výzkumu, včetně přírodních věd, materiálových věd, chemické syntézy, chromatografie, analytiky a mnoha dalších..

Obraťte se na technický servis.